Sorafenib¿¡ ºÎºÐ ¹ÝÀÀÀ» º¸ÀÎ Æó ÀüÀÌ °£¼¼Æ÷¾ÏÁ¾ 1¿¹
A Case of Pulmonary Metastasis from Hepatocellular Carcinoma Partially Responsive to Sorafenib
´ëÇÑ°£¾Ï¿¬±¸ÇÐȸÁö 2010³â 10±Ç 1È£ p.52 ~ p.54
Çã³»À±(Heo Nae-Yun) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼¿ï¾Æ»êº´¿ø ¼Òȱ⳻°úÇб³½Ç
ÀÌ¿µ»ó(Lee Yung-Sang) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼¿ï¾Æ»êº´¿ø ¼Òȱ⳻°úÇб³½Ç
¼µ¿Áø(Suh Dong-Jin) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼¿ï¾Æ»êº´¿ø ¼Òȱ⳻°úÇб³½Ç
Á¤¿µÈ(Chung Young-Hwa) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼¿ï¾Æ»êº´¿ø ¼Òȱ⳻°úÇб³½Ç
ÀÓ¿µ¼®(Lim Young-Suk) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼¿ï¾Æ»êº´¿ø ³»°úÇб³½Ç
½ÉÁÖÇö(Shim Ju-Hyun) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼¿ï¾Æ»êº´¿ø ³»°úÇб³½Ç
ÀÌÇÑÁÖ(Lee Han-Chu) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼¿ï¾Æ»êº´¿ø ³»°úÇб³½Ç
Abstract
Hepatocellular carcinoma (HCC) is one of the most important causes of cancer death in South Korea. Unfortunately, more
than half of the patients are diagnosed in the advanced stage with multiple intra- or extrahepatic metastasis, so no more than 30% of patients are suitable to undergo curative resection. Lung is the most common organ of extrahepatic metastasis of HCC, and the pulmonary metastasis is known as poor prognosis factor, but no standard systemic therapy is established yet. Sorafenib is the only molecularly targeted agent which has been proven clinical benefit in the randomized clinical trials, but pulmonary metastasis is known as predictive factor of poor response. However, we experience a case of pulmonary metastasis from hepatocellular carcinoma partially responsive to sorafenib, and report it.
Å°¿öµå
Pulmonary metastasis, Hepatocellular carcinoma, Sorafenib
KMID :
0964020100100010052
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
This case of patient with pulmonary metastasis from hepatocellular carcinoma was partially responsive to Sorafenib.